Cost-effectiveness of cardiac biomarkers as screening test in acute chest pain. | Zendy

Samad Shams Vahdati | Zendy; Zahra Vand-Rajavpour | Zendy; Seyed Pouya Paknezhad | Zendy; Reza Piri | Zendy; Elnaz Moghaddasi-Ghezeljeh | Zendy; Saba Mirabolfathi | Zendy; Mohammad Naghavi-Behzad | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost-effectiveness of cardiac biomarkers as screening test in acute chest pain.

Author(s) -

Samad Shams Vahdati,

Zahra Vand-Rajavpour,

Seyed Pouya Paknezhad,

Reza Piri,

Elnaz Moghaddasi-Ghezeljeh,

Saba Mirabolfathi,

Mohammad Naghavi-Behzad

Publication year - 2014

Publication title -

pubmed

Language(s) - English

Resource type - Journals

eISSN - 2008-6830

pISSN - 2008-5117

DOI - 10.5681/jcvtr.2014.006

Subject(s) - medicine , chest pain , myocardial infarction , acute coronary syndrome , troponin , emergency department , cardiology , unstable angina , creatine kinase , cardiac marker , angina , pre and post test probability , psychiatry

Acute chest pain is an important and frequently occurring symptom in patients. Chest pain is often a sign of ischemic heart disease. Associated findings of electrocardiograph (ECG) are rather heterogeneous, and traditional cardiac biomarkers such as Creatine Kinase-MB (CK-MB) suffer from low cardiac specificity and sensitivity. In this study cost effectiveness of cardiac biomarkers single quantitative measurement was examined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research